Please login to the form below

Not currently logged in
Email:
Password:

Trial success for Forest's depression drug

Forest Laboratories has said preliminary results from a phase III trial of major depressive disorder treatment, levomilnacipran, indicate the drug achieved a statistically significant improvement in patients compared to placebo

Forest Laboratories has said preliminary results from a phase III trial of major depressive disorder treatment, levomilnacipran, indicate the drug achieved a statistically significant improvement in patients compared to placebo.

The drug's efficacy was based on the primary endpoint of a patient's change from baseline to end of week 8 in the Montgomery-Asberg Depression Rating Scale-Clinician Rated (MADRS-CR) total score.

Levomilnacipran is co-developed by Forest and France-based laboratory Pierre Fabre Medicament.

"These positive phase III results are very encouraging and support the continued research of levomilnacipran in adult patients with major depressive disorder," said Dr Marco Taglietti, senior vice president, R&D, and president, Forest Research Institute.

Further analysis of the study data is ongoing, with two additional placebo-controlled phase III studies expected at the end of 2011 and in spring 2012, respectively.

18th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics